Novartis AG (NVS) Stock AnalysisNVSNovartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Novartis AG (NVS) is a good buy right now, trading at $143.75 with a forward P/E of 14.71, indicating potential for growth compared to its current valuation. The recent $7.8 billion deal with Abogen Biosciences highlights Novartis's commitment to innovation in drug development, which is crucial as several blockbuster drugs are facing patent expirations by 2030. Additionally, the stock has shown a solid 11.33% increase over the past year, suggesting a positive long-term trend. However, the main risk is the recent downgrade in price targets from analysts, with Morgan Stanley lowering its target from $170 to $156, reflecting concerns over clinical execution risks. Overall, the strong fundamentals and strategic partnerships position Novartis favorably for long-term investors.

3 analysts cover NVS: 1 rate it Buy, 2 Hold and 0 Sell. The average price target is 127.75.